As novel therapies like blinatumomab and ponatinib achieve excellent systemic control of B-ALL, central nervous system (CNS) relapse emerges as a primary hurdle. This was noted in this trial and others, highlighting a critical unmet need to develop effective, non-chemotherapeutic strategies for CNS prophylaxis and treatment.
The blinatumomab/ponatinib combination for Ph+ B-ALL achieves deep remissions, allowing nearly 80% of patients to avoid allogeneic stem cell transplants. This signals a new paradigm where avoiding the significant toxicities and quality of life impairments of transplant is a primary treatment goal, not just a secondary benefit.
In the era of potent targeted therapies for Philadelphia chromosome-positive B-ALL, the most critical factor for deciding on a consolidative allogeneic stem cell transplant is persistent minimal residual disease (MRD). This response-based metric has become more important than baseline mutational status for upfront risk stratification and treatment planning.